Literature DB >> 20587609

The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma-2 with nuclear receptor co-repressor.

Sadako Suzuki1, Shigekazu Sasaki, Hiroshi Morita, Yutaka Oki, Daisuke Turiya, Takeshi Ito, Hiroko Misawa, Keiko Ishizuka, Hirotoshi Nakamura.   

Abstract

Peroxisome proliferator-activated receptor gamma-2 (PPARG2) is a ligand-dependent transcriptional factor involved in the pathogenesis of insulin resistance. In the presence of a ligand, PPARG2 associates with co-activators, while it recruits co-repressors (CoRs) in the absence of a ligand. It has been reported that the interaction of liganded PPARG2 with co-activators is regulated by the amino-terminal A/B domain (NTD) via inter-domain communication. However, the role of the NTD is unknown in the case of the interaction between unliganded PPARG2 and CoRs. To elucidate this, total elimination of the influence of ligands is required, but the endogenous ligands of PPARG2 have not been fully defined. PPARG1-P467L, a naturally occurring mutant of PPARG1, was identified in a patient with severe insulin resistance. Reflecting its very low affinity for various ligands, this mutant does not have transcriptional activity in the PPAR response element, but exhibits dominant negative effects (DNEs) on liganded wild-type PPARG2-mediated transactivation. Using the corresponding PPARG2 mutant, PPARG2-P495L, we evaluated the role of the NTD in the interaction between unliganded PPARG2 and CoRs. Interestingly, the DNE of PPARG2-P495L was increased by the truncation of its NTD. NTD deletion also enhanced the DNE of a chimeric receptor, PT, in which the ligand-binding domain of PPARG2 was replaced with that of thyroid hormone receptor beta-1. Moreover, NTD deletion facilitated the in vitro binding of nuclear receptor CoR with wild-type PPARG2, mutant P495L, and the PT chimera (PPARG2-THRB). Inter-domain communication in PPARG2 regulates not only ligand-dependent transactivation but also ligand-independent silencing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587609     DOI: 10.1677/JME-10-0007

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  8 in total

Review 1.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 2.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

Review 3.  Discovering and understanding oncogenic gene fusions through data intensive computational approaches.

Authors:  Natasha S Latysheva; M Madan Babu
Journal:  Nucleic Acids Res       Date:  2016-04-21       Impact factor: 16.971

4.  DNA polymerase β variant Ile260Met generates global gene expression changes related to cellular transformation.

Authors:  Katherine A Donigan; David Tuck; Vince Schulz; Joann B Sweasy
Journal:  Mutagenesis       Date:  2012-08-21       Impact factor: 3.000

5.  Novel domain combinations in proteins encoded by chimeric transcripts.

Authors:  Milana Frenkel-Morgenstern; Alfonso Valencia
Journal:  Bioinformatics       Date:  2012-06-15       Impact factor: 6.937

6.  Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.

Authors:  Pora Kim; Leomar Y Ballester; Zhongming Zhao
Journal:  Oncotarget       Date:  2017-11-24

7.  Human transcription factor and protein kinase gene fusions in human cancer.

Authors:  Kari Salokas; Rigbe G Weldatsadik; Markku Varjosalo
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

8.  Isoform-specific functions of PPARγ in gene regulation and metabolism.

Authors:  Wenxiang Hu; Chunjie Jiang; Mindy Kim; Yang Xiao; Hannah J Richter; Dongyin Guan; Kun Zhu; Brianna M Krusen; Arielle N Roberts; Jessica Miller; David J Steger; Mitchell A Lazar
Journal:  Genes Dev       Date:  2022-03-10       Impact factor: 12.890

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.